Le Lézard
Classified in: Health, Science and technology
Subjects: Conference, Event

Aptorum Group Limited Announces Results of 2019 Annual General Meeting


Aptorum Group Limited (Nasdaq: APM) ("the Company") a biopharmaceutical company focused on the development of novel therapeutics to address certain global unmet medical needs, announced today the results of its 2019 Annual General Meeting, which was held on November 14, 2019, in Hong Kong.

At the Annual General Meeting, shareholders

About Aptorum Group Limited

Aptorum Group Limited (Nasdaq: APM) is a pharmaceutical company dedicated to developing and commercializing novel therapeutics to tackle certain unmet medical needs. Aptorum Group is pursuing therapeutic projects in neurology, infectious diseases, gastroenterology, oncology and other disease areas.

For more information about Aptorum Group, please visit www.aptorumgroup.com.

Disclaimer and Forward-Looking Statements

This press release includes statements concerning Aptorum Group Limited and its future expectations, plans and prospects that constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. For this purpose, any statements contained herein that are not statements of historical fact may be deemed to be forward-looking statements. In some cases, you can identify forward-looking statements by terms such as "may," "should," "expects," "plans," "anticipates," "could," "intends," "target," "projects," "contemplates," "believes," "estimates," "predicts," "potential," or "continue," or the negative of these terms or other similar expressions. Aptorum Group has based these forward-looking statements largely on its current expectations and projections about future events and trends that it believes may affect its business, financial condition and results of operations. These forward-looking statements speak only as of the date of this press release and are subject to a number of risks, uncertainties and assumptions including, without limitation, risks related to its announced management and organizational changes, the continued service and availability of key personnel, its ability to expand its product assortments by offering additional products for additional consumer segments, the company's anticipated growth strategies, anticipated trends and challenges in its business, and its expectations regarding, and the stability of, its supply chain, and the risks more fully described in Aptorum Group's Form 20-F and other filings that Aptorum Group may make with the SEC in the future. Aptorum Group assumes no obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise.


These press releases may also interest you

at 15:00
Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of LogicBio Therapeutics, Inc. between December 3, 2018 and February 10, 2020, inclusive (the "Class Period") of the important May 18, 2020 lead plaintiff...

at 14:30
Disaster Management Group, a South Florida-based disaster recovery firm, announced today DMGtest, a screening tool for COVID-19 that gives results in 15 minutes. The test is the first of its kind used in Florida to screen for coronavirus. DMGtest...

at 14:02
On behalf of the Québec government, Minister of Tourism Caroline Proulx today announced the closing until further notice of tourist accommodation establishments. There are two exceptions to the rule: certain campgrounds that host snowbirds who do not...

at 14:00
Confluent Health is proud to announce their newest partnership, El Paso Physical Therapy Services (EPPTS), a physical therapist-owned rehabilitation company since 1985 specializing in the treatment of orthopedic, sports, and work-related injuries...

at 11:23
Today, Samaritan's Purse deployed its Emergency Field Hospital to New York City, New York, where the local medical infrastructure is severely overwhelmed. In cooperation with the Federal Emergency Management Agency (FEMA), New York state officials,...

at 11:01
Novartis today announced results from a prespecified analysis of pooled data from three Phase III studies evaluating the safety and efficacy of inclisiran, its first-in-class investigational treatment for hyperlipidemia in adults. The data was...



News published on 15 november 2019 at 08:05 and distributed by: